Skip to main content
. 2024 Mar 12;25(6):3222. doi: 10.3390/ijms25063222

Figure 4.

Figure 4

Drug–drug interactions between ART and biological anticancer agents according to Medscape, Liverpool University, and PEPID interaction checkers’ reports. Legend: no interaction expected (green); potential weak interaction (yellow); potential interaction (orange); do not co-administer (red); unknown interactions (grey). ADCs: antibody drug conjugates; CDK4/6i: cyclin-dependent kinase 4/6 inhibitors; PARPi: poly(ADP) ribose polymerase inhibitors; SG: sacituzumab govitecan; T-DM1: trastuzumab emtansine; T-Dxd: trastuzumab deruxtecan; NNRTIs: non-nucleoside reverse transcriptase inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; PIs: protease inhibitors; ABC: abacavir; ABT: albuvirtide; ATV: atazanavir; AZT: zidovudine; BIC: bictegravir; CAB: cabotegravir; c: cobicistat; DPV: dapivirine; DRV: darunavir; DOR: doravirine; DTG: dolutegravir; EFV: efavirenz; ENF: enfuvirtide; EVG: elvitegravir; ETR: etravirine; FTC: emtricitabine; FTR: fostemsavir; IBA: ibalizumab-uiyk; MVC: maraviroc; NVP: nevirapine; RAL: raltegravir; RPV: rilpivirine; RTV/r: ritonavir; TAF: tenofovir alafenamide; TDF: tenofovir-disoproxil fumarate; 3TC: lamivudine.